In this minireview, we aim to shed light on the roles of PBRM1, SETD2, and BAP1 in the tumor metabolic and immune microenvironments, and discuss how these functions could benefit the management of advanced ccRCC. This evidence concerns the gene PBRM1 and neoplasm.